Oncopeptides AB's drug received a positive opinion from the EMA, leading to the European Commission making a final decision for the EU market.
1 report, 1 independent
Updated Sep 17
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Oncopeptides AB's drug received a positive opinion from the EMA, leading to the European Commission making a final decision for the EU market.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
European Commission
executive branch of the European Union
-
European Medicines Agency
highest regulatory authority on medicines in the European Union
Related events
- EMA adopted a positive opinion for Sobi's drug, with the European Commission set to confirm the decision.
- Alvotech submitted a regulatory application to the European Medicines Agency (EMA).
- Both the FDA and the European Medicines Agency govern drug approval processes.
- Ascendis Pharma A/S received FDA approval and is moving forward with its first EU launch in Germany.
- Omeros Corporation's drug received FDA approval and is currently undergoing review by the European Medicines Agency.